There is one small pilot study in humans (examining knee pain, where 7 of 12 participants reported sustained improvement beyond 6 months) and a 2025 safety study confirming BPC-157 was well tolerated in healthy adults
Cell Cycle 12:21632164 Jopling HM, Odell AF, Pellet-Many C, Latham AM, Frankel P, Sivaprasadarao A, Walker JH, Zachary IC, Ponnambalam S (2014) Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation
This study continued that pattern: No serious adverse events were reported in any patient Minor injection site reactions (mild redness or swelling) were reported in 15% of patients and resolved without intervention No systemic effects, no changes in standard bloodwork panels No interactions with concurrent medications were observed This safety record across both animal and now human data is part of what makes BPC-157 a credible candidate for broader clinical adoption
As one expert says, Regular monitoring is essential to tailor Vitamin B12 therapy to individual patient needs and prevent over- or under-treatment. Response-Based Dosing Strategies We adjust Vitamin B12 doses based on how well the patient responds
Studies show it activates the JAK2 signaling pathway, enhancing cells ability to respond to growth hormone and accelerating tissue regeneration
